Evan Jones, Chairman and CEO
Mr. Jones is the Chairman and CEO of OpGen and also is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute.
Mr. Jones received a B.A. degree from the University of Colorado and an M.B.A. from The Wharton School, University of Pennsylvania.
Timothy Dec, Chief Financial Officer
Mr. Dec, has more than 20 years of public company financial leadership experience in technology and healthcare companies. He has served in chief financial officer or other senior financial executive roles at companies in a number of industries, including three publicly traded companies listed on NASDAQ or AMEX, such as Corvis Corporation, and at private equity-backed companies. Prior to joining OpGen, Mr. Dec served as Senior Vice President and Chief Financial Officer for Clubwidesports, LLC, a start-up sports management software company, from January 2014 to April 2015. From August 2007 to December 2012, He was Senior Vice President and Chief Financial Officer of Fortress International Group, Inc., a publicly traded company. Mr. Dec also has public accounting firm experience. He is an adjunct professor at Mount St. Mary’s University in Emmitsburg, Maryland, where he teaches M.B.A. courses in Finance.
Mr. Dec holds a B.S. in accounting from Mount Saint Mary’s University, and an M.B.A. from American University in Washington, DC.
Vadim Sapiro, Chief Information Officer
Mr. Sapiro joined OpGen in December, 2011 with responsibility for leading the development of the Company’s bioinformatics applications, software, databases and information technology operations. Prior to OpGen, he was senior vice president at SAIC-Frederick overseeing the Information Systems Program for the National Cancer Institute at Frederick with responsibility for information technology, scientific computing and bioinformatics. Among his projects were technical program management and operations for the cancer Biomedical Informatics Grid (caBIG™), the cancer Human Biobank (caHUB) and The Cancer Genome Atlas (TCGA). Prior to SAIC, Mr. Sapiro was vice president for information technology with the J. Craig Venter Institute. He is active in the regional and national technology and research communities, having served on many life sciences and biotech focused advisory boards and review committees.
Mr. Sapiro holds a B.S. in Mathematics and Computer Science from the University of Maryland.
Michael Farmer, Vice President, Marketing
Mr. Farmer joined OpGen in 2012 and is responsible for all global commercial activities related to the FDA-cleared, IVD products and CLIA-certified clinical laboratory services. He has 25 years of experience in the biotechnology and IVD industries, most of which focused on the commercialization of molecular diagnostic technologies, including world-wide product launches. Prior to OpGen, he held various marketing and strategic leadership positions at Qiagen, Becton Dickinson, Digene, and Life Technologies/Invitrogen (now Thermo Fisher Scientific). Additionally, he is an adjunct professor at Johns Hopkins University where he teaches courses in Marketing.
Mr. Farmer holds a B.S. in Biology from Virginia Commonwealth University, and an M.B.A from Carey Business School, Johns Hopkins University.
Thomas Guiel, Vice President, Operations
Mr. Guiel is responsible for FDA-cleared, IVD product manufacturing, CLIA-certified clinical laboratory services, quality assurance and regulatory affairs, as well as, logistics for both the Gaithersburg, MD and Woburn, MA sites. He has more than 30 years of industry experience within the biotechnology industry, managing product and service operations. Before joining OpGen, he was the COO at OncoPlex Diagnostics where he established a CLIA-certified laboratory to identify and quantitate specific drug-target proteins in FFPE oncology specimens employing a multiplexed SRM mass spectrometry assay. Mr. Guiel was at Life Technologies/Invitrogen (now Thermo Fisher Scientific) for 18 years. There, he was responsible for establishing global ordering and distribution, manufacturing operations, and partnerships in Japan, New Zealand, Brazil, the U.K. and throughout the U.S.
Mr. Guiel holds a B.A. in Chemistry from Rochester Institute of Technology.
Terry Walker, Ph.D., Sr. VP, Research & Development
Dr. Walker’s responsibilities include leading the development of genomic technologies and new products supporting molecular diagnostics for infectious diseases. Prior to OpGen, He previously led drug target validation, biomarker discovery and clinical diagnostic development at Pfizer, GlaxoSmithKline (GSK), Becton Dickinson (BD), Duke University and The Biomarker Factory across most disease areas and stages of development from discovery through late clinical trials.
Dr. Walker received his Ph.D. in Biophysical Chemistry from the University of Rochester with postdoctoral training in Biophysical Chemistry at the University of California, Berkeley.